A Map to Undercutting Medical Overuse

Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.

Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.

RAD 2025: Renowned AD investigator Kircik provides the history behind the class-wide black box warning, highlights JAK inhibitor efficacy, and toplines exciting AD research.

Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.

Cycling and mixed cycling were associated with a reduced risk of all-cause dementia, including of young onset, as well as increased hippocampal volume.